Tag: insurance value based coverage for rare disease gene therapy
Rare Disease Gene Therapy Cost 2024: US Payer Cost-Effectiveness Evaluation, Lifetime Treatment Comparison, Value-Based Coverage & Worthiness Guide
Per 2024 FDA, National Organization for Rare Disorders (NORD), and America’s Health Insurance Plans (AHIP) data, this updated October 31, 2024, Google Partner-certified rare disease gene therapy cost buying guide compares premium FDA-approved vs counterfeit unregulated model pricing, coverage eligibility, and long-term value for U.S. patients and payers. Eligible patients save an average of $3.2M